AI and CRISPR technologies power proactive health monitoring

JMIR Publications today featured two new articles in its News and Outlook section highlighting the transition to proactive, technology-integrated health monitoring. These latest articles explore how existing medical screenings can be repurposed with AI and how the world’s most advanced diagnostic tools are being miniaturized for everyday use.

1. AI and mammograms: Uncovering hidden heart health data

In a new feature, “Breast artery calcification quantified with AI can predict heart disease risk from mammograms,” JMIR correspondent Shalini Katuria Narang talks about how artificial intelligence is being used to transform routine breast cancer screenings into dual-purpose health exams. By analyzing breast artery calcification (BAC), AI models can now help clinicians identify women at high risk for cardiovascular disease, often the leading cause of death in women, without the need for additional appointments or blood tests.

Key insights:

• Automated risk scoring: AI accurately measures calcium accumulation. Every square millimeter of calcification increases cardiovascular risk by 1%.

• Active care for young women: The feature notes that this AI analysis is particularly valuable for women under 50, who are often overlooked by traditional heart disease screening models.

• Seamless integration: Because data is extracted from existing mammograms, this approach provides a low-barrier, cost-effective way to close the gender gap in heart disease diagnosis.

  
  
  

2. CRISPR-on-a-chip: Lab-quality diagnostics in your pocket

In the second feature, “CRISPR Diagnostics, in Your Pocket,” Dr. Cliff Dominy explores the intersection of gene editing technology and microfluidics. The emerging technology, known as “CRISPR-on-a-chip,” aims to provide laboratory-grade precision for detecting infectious diseases and early cancer markers through a portable device linked to a smartphone.

Key insights:

• Hypersensitivity: By taking advantage of the unique properties of the CRISPR enzyme, these chips are 10 to 100 times more sensitive than standard PCR tests.

• Single molecule detection: This article highlights the potential for graphene-based sensors to detect single molecules of tumor DNA in the bloodstream, long before physical symptoms appear.

• Accessibility: These devices could soon enable highly accurate testing at a patient’s bedside or at home, moving diagnostics away from bulky laboratory infrastructure.

A vision for proactive health

Taken together, these stories paint a picture of an increasingly proactive future of medicine. Whether by extracting new insights from routine imaging or incorporating molecular-grade tests into pocket-sized devices, these technological changes represent new frontiers in the effort to detect and manage disease earlier than ever before.